Literature DB >> 23055011

Anaplastic thyroid cancer therapy: dream or reality?

Rossella Elisei.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23055011     DOI： 10.1007/s12020-012-9785-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

2.  AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.

Authors:  Silvana Libertini; Antonella Abagnale; Carmela Passaro; Ginevra Botta; Sara Barbato; Paolo Chieffi; Giuseppe Portella
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

3.  CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

Authors:  Alessandro Antonelli; Guido Bocci; Concettina La Motta; Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Andrea Di Domenicantonio; Anna Fioravanti; Stefania Sartini; Michele Minuto; Simona Piaggi; Alessandro Corti; Greta Alì; Teresa Di Desidero; Piero Berti; Gabriella Fontanini; Romano Danesi; Federico Da Settimo; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

4.  Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.

Authors:  Annette Wunderlich; Tjadina Arndt; Melina Fischer; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

5.  Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.

Authors:  Sepideh Gholami; Dana Haddad; Chun-Hao Chen; Nanhai G Chen; Qian Zhang; Pat B Zanzonico; Aladar A Szalay; Yuman Fong
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

6.  Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.

Authors:  Wen-Bin Zhong; Sung-Po Hsu; Pei-Yin Ho; Yu-Chih Liang; Tien-Chun Chang; Wen-Sen Lee
Journal:  Biochem Pharmacol       Date:  2011-09-02       Impact factor: 5.858

7.  Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid.

Authors:  Rossella Elisei; Agnese Vivaldi; Raffaele Ciampi; Pinuccia Faviana; Fulvio Basolo; Ferruccio Santini; Claudio Traino; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2006-03-14       Impact factor: 5.958

8.  Phase II trial of sorafenib in advanced thyroid cancer.

Authors:  Vandana Gupta-Abramson; Andrea B Troxel; Anoma Nellore; Kanchan Puttaswamy; Maryann Redlinger; Kathy Ransone; Susan J Mandel; Keith T Flaherty; Laurie A Loevner; Peter J O'Dwyer; Marcia S Brose
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

9.  Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.

Authors:  Yannick Arlot-Bonnemains; Enke Baldini; Benedicte Martin; Jean-Guy Delcros; Matteo Toller; Francesco Curcio; Francesco S Ambesi-Impiombato; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocr Relat Cancer       Date:  2008-04-22       Impact factor: 5.678

10.  Treatment outcome of patients with anaplastic thyroid cancer: a single center experience.

Authors:  Sun Min Lim; Sang-Joon Shin; Woong Youn Chung; Cheong Soo Park; Kee-Hyun Nam; Sang-Wook Kang; Ki Chang Keum; Joo Hang Kim; Jae Yong Cho; Yun Kyoung Hong; Byoung Chul Cho
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759
  10 in total
  5 in total

1.  MCM5 as a target of BET inhibitors in thyroid cancer cells.

Authors:  Catia Mio; Elisa Lavarone; Ketty Conzatti; Federica Baldan; Barbara Toffoletto; Cinzia Puppin; Sebastiano Filetti; Cosimo Durante; Diego Russo; Arturo Orlacchio; Antonio Di Cristofano; Carla Di Loreto; Giuseppe Damante
Journal:  Endocr Relat Cancer       Date:  2016-02-24       Impact factor: 5.678

2.  Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells.

Authors:  Raktim Biswas; Phil-Sang Chung; Jeong Hwan Moon; Seung-Ha Lee; Jin-Chul Ahn
Journal:  Lasers Med Sci       Date:  2013-10-10       Impact factor: 3.161

3.  PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Massimiliano Volpe; Ginevra Botta; Eloise Scamardella; Giuseppe Perruolo; David Gillespie; Silvana Libertini; Giuseppe Portella
Journal:  Mol Oncol       Date:  2014-08-02       Impact factor: 6.603

4.  Expression of hedgehog signalling pathway in anaplastic thyroid cancer.

Authors:  Ulrike Hinterseher; Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Detlef K Bartsch; Stefan Hauptmann; Brandon H Greene; Volker Fendrich; Sebastian Hoffmann
Journal:  Endocrine       Date:  2013-07-17       Impact factor: 3.633

Review 5.  Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Authors:  Cosimo Durante; Alessandra Paciaroni; Katia Plasmati; Fabiana Trulli; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-04-14       Impact factor: 3.633
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.